Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Osteopore Ltd. ( (AU:OSX) ).
Osteopore Limited has completed the final A$500,000 drawdown of Tranche 1 of its 4.0% redeemable convertible notes under a subscription agreement with Advance Opportunities Fund and Advance Opportunities Fund I, bringing the total nominal amount issued under the first A$5 million tranche to A$5 million across 20 sub‑tranches. The fresh capital will be deployed to support Osteopore’s ordinary operations and fund future developments, projects and investments as opportunities arise, bolstering the company’s financial flexibility as it pursues growth in regenerative medicine and 3D‑printed implant markets.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
More about Osteopore Ltd.
Osteopore Limited is a Singapore-founded, Australian‑listed regenerative medicine company that is a global leader in 3D‑printed biomimetic and bioresorbable implants. It commercialises patented scaffold products that use naturally dissolving polymers to stimulate natural bone healing across multiple clinical segments, aiming to reduce post-surgery complications associated with permanent bone implants.
Average Trading Volume: 23,076,087
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.76M
For detailed information about OSX stock, go to TipRanks’ Stock Analysis page.